Please ensure Javascript is enabled for purposes of website accessibility

Here's​ ​Why Cellectis SA Fell as Much as 31.6% Today

By Maxx Chatsko - Sep 5, 2017 at 2:15PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biopharma became the latest in the CAR-T space to receive a clinical hold from the FDA.

What​ ​happened

Shares of biopharma Cellectis (CLLS 2.88%) fell nearly 32% today after the company announced that the U.S. Food and Drug Administration had placed a clinical hold on its second leading product candidate, UCART123. The regulatory hold affects two ongoing phase 1 trials aimed at treating acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN).

Today's news comes just days after Gilead Sciences reinvigorated the immunotherapy space by acquiring Kite Pharma in a blockbuster deal; for investors, it brings back unpleasant memories of Juno Therapeutics' clinical hold in summer 2016. The company is also developing chimeric antigen receptor T cell (CAR-T) immunotherapies for oncology indications.

As​ ​of​ ​1:27 p.m.​ ​EDT,​ ​the​ ​stock​ ​had​ ​settled​ ​to​ ​a​ ​20.1%​ ​loss.

A businessman looking down a stock chart showing losses

Image source: Getty Images.

So​ ​what

Cellectis provided a good level of detail about its preliminary knowledge of the event -- a patient death in the BPDCN trial -- that triggered the clinical hold. It will now work with the FDA in an attempt to resume the trials and alter the protocols to increase patient safety.

While an unfortunate development for patients and investors, the news doesn't appear to be having much of an effect on the rest of the CAR-T space. That's refreshing, considering the major corrections that were catalyzed last summer by the Juno Therapeutics clinical hold.

However, bluebird bio (BLUE -2.50%) shares are also down today on the news from Cellectis. Most likely that's because both Cellectis and Bluebird rely on the same gene-editing technology (TALEN) for altering their therapeutic CAR-T cocktails. Whether or not it had anything to do with the patient death, or potential off-target effects, remains to be seen.

Now​ ​what

This is certainly a blow to Cellectis investors, but there's nothing they can do except wait. It's seems likely that the FDA will allow the trials to resume with modifications and further investigation, but that doesn't guarantee they'll be continued by management. Uncertainty is never kind to a stock.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Cellectis Stock Quote
$3.21 (2.88%) $0.09
bluebird bio, Inc. Stock Quote
bluebird bio, Inc.
$4.29 (-2.50%) $0.11

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.